Background: Glucocorticoid excess has been linked with cardiovascular disease. Little is known about the long-term cortisol response in patients after acute coronary syndrome. Design: The objective of this study was to describe the distribution of salivary cortisol in the post-acute phase of acute coronary syndrome and to describe the association of late-night salivary cortisol with cardiovascular risk factors. Methods: We used late-night salivary cortisol measurements post-discharge to estimate hypothalamic-pituitary-adrenal axis activity in 309 patients aged 18-55 years enrolled in the GENESIS-PRAXY study from January 2009-April 2013. We evaluated hypothalamic-pituitary-adrenal axis activity and its association with hypertension, dyslipidemia, diabetes, smoking, family history, prior acute coronary syndrome, psychiatric diseases, acute coronary syndrome severity, as well as mortality and rate of rehospitalization at 12 months. Results: Persistently elevated late-night salivary cortisol>2.92 nmol/l was seen in 99 (32.0%) patients: within the range of what may be seen in Cushing's disease. Elevated late-night salivary cortisol was associated with previous acute coronary syndrome (13.3% vs 24.2%, p ¼ 0.02), peripheral vascular disease (3.8% vs 13.1%, p ¼ 0.002), and smoking (32.9% vs 46.5% p ¼ 0.02). Elevated late-night salivary cortisol was associated with higher hemoglobin A1c values (5.6 AE 3.0 vs 6.1 AE 2.9, p ¼ 0.008) and lower high density lipoprotein values (0.94 AE 0.53 vs 0.86 AE 0.50, p ¼ 0.01). There were no differences in psychiatric symptom scores, acute coronary syndrome severity or mortality, and rate of rehospitalization at 12 months. Conclusions: Many patients post-acute coronary syndrome have prolonged, marked activation of the hypothalamicpituitary-adrenal axis. Late-night salivary cortisol co-associates with several cardiovascular risk factors. Further studies are needed to confirm the exact role of hypothalamic-pituitary-adrenal axis activity in the pathophysiology of cardiovascular disease.
Introduction
Cortisol, the main glucocorticoid of the hypothalamicpituitary-adrenal (HPA) axis, has a multitude of effects on the metabolism of protein, fat, and carbohydrates as well as the cardiovascular and immune systems that can predispose to cardiovascular disease (CVD). Indeed, sustained glucocorticoid excess, by either exogenous exposure 1 or endogenous overproduction (Cushing's syndrome), 2 has been linked with CVD due to the hormone's effects on promoting visceral adiposity, hypertension, dyslipidemia, and glucose intolerance.
HPA activation occurs in response to acute physiologic stress as well as chronic psychological stress, e.g. depression and anxiety. 3, 4 Depression and anxiety are also associated with an increased risk of CVD 5 and adverse CVD outcomes. 6 Increased HPA activity may be a putative mechanism that underlies this association. 7 The primary objective of this study was to examine salivary cortisol levels and determine the levels of HPA axis activation following discharge from hospital in a cohort of patients with acute coronary syndrome (ACS). Secondarily, this study sought to examine potential associations between latent increased HPA axis activity with traditional and non-traditional CVD risk factors in ACS survivors.
Methods

Study population
The study population consisted of patients enrolled in GENESIS-PRAXY (GENdEr and Sex determInantS of cardiovascular disease: from bench to beyondPremature Acute Coronary SYndrome), a multicenter, prospective cohort study of adults hospitalized with ACS. The methods of the GENESIS-PRAXY study have been previously described. 8 Eligible participants included patients aged 18-55 years, admitted with a diagnosis of ACS from January 2009-April 2013. The ACS case definition has been described previously; eligible patients had symptoms consistent with cardiac ischemia and either electrocardiographic changes or biochemical changes with increased cardiac enzymes. 8 The study included 24 sites across Canada, one in the USA, and one in Switzerland. In this cohort, only one patient was taking exogenous steroids and this patient was excluded from the analysis.
Data collection
Study participants were identified, consented and enrolled within 48 h of hospital admission. Medical chart reviews were completed at baseline and 12 months to collect clinical data. Patients were asked to complete a self-administered questionnaire at the time of enrolment and at one, six, and 12 months post-event. The questionnaires included the Hospital Anxiety and Depression Scale (HADS): a validated self-report questionnaire used to estimate the severity of anxious and depressive symptoms. 9 A score of eight or more on the respective subscales of HADS was used to indicate levels of symptoms that have been associated with clinical depression and anxiety: this cut-off has been demonstrated to have a sensitivity of 0.90 and specificity of 0.78 for the diagnosis of depression and a sensitivity of 0.83 and specificity of 0.79 for identifying patients with anxiety disorders. 10 A subset of the GENESIS-PRAXY study patients were given salivette collection kits and asked to collect saliva samples at midnight on two consecutive nights following hospital discharge. The samples were collected within 90 days of discharge (median 26 days with an interquartile range of 29) and were mailed to a central laboratory at the Douglas Hospital in Montre´al, Que´bec, Canada. Salivary cortisol was measured by enzyme immunoassay (Salimetrics, State College, Pennsylvania, USA). Mean intra-assay precision is reported to be 7%, 5%, 3%, 4%, and 4% for salivary cortisol levels of 1.65, 4.40, 11.57, 31.4 and 57.02 nmol/L respectively. 11 The two salivary cortisol results were averaged to generate a single mean late-night salivary cortisol (LNSC) estimate for each participant.
Definition of HPA axis activation using salivary cortisol
The primary biochemical outcome definition was derived from a recent study by Bukan et al. that examined LNSC levels using the EIA Salimetrics kit. A LNSC level greater than 2.92 nmol/l had a sensitivity of 100% and specificity of 96.7% to differentiate Cushing's disease (a condition of autonomous overproduction of cortisol that is strongly associated with a number of adverse health outcomes including CVD) from healthy individuals. 12 A similar cut-off was also reported in an older study by Restituto et al. using an EIA assay. 13 Therefore, we defined a mean LNSC of greater than 2.92 nmol/l as indicative of clinically relevant HPA axis activation. 2 
Statistical analysis
We compared continuous variables using two-sample t-tests and compared dichotomous variables with 2 tests. The relationship between salivary cortisol and continuous variables was tested using r 2 . All statistical analysis was performed using SAS version 9.2 (Cary, North Carolina, USA). Statistical tests were two-sided; differences with p 0.05 were considered statistically significant. Patients with missing data or incomplete records were excluded from analysis.
Results
The baseline participant characteristics according to the primary HPA activation definition are shown in Table 1 and the LNSC distributions are displayed in Figure 1 . Table 2 outlines the correlation coefficient between salivary cortisol and some population characteristics. The majority of participants were white and male. In most cases, ACS was the first-ever presentation of CVD. Most of the traditional CVD risk factors were equally prevalent among both the HPA-activation and HPA-normal groups including obesity, diabetes, dyslipidemia, and hypertension. However, those with HPA axis activation had a statistically significantly higher rate of previous clinical CVD and peripheral vascular disease. HPA axis activation was associated with higher hemoglobin A1c (HbA1c) values; however, this relationship was not clearly linear (r 2 ¼ 0.083, p ¼ 0.18). HPA axis activation was also associated with lower high-density lipoprotein (HDL) levels in a linear fashion (r 2 ¼ -0.13, p ¼ 0.02). HPA axis activation was also more common among smokers (p ¼ 0.02). The TIMI and GRACE scores are markers of ACS severity and neither differed according to HPA activation group, suggesting that the persistent HPA activation seen was not explained simply on the basis of more severe clinical ACS disease. There was no difference between the groups in re-hospitalization or mortality at 12 months, although such events were very uncommon. Using the Cox proportional hazard model, there was no statistically significant difference in re-hospitalization (hazard ratio (HR) 1.1; 95% confidence interval (CI) 0.49-2.5) or death (HR 0.99; 0.51-1.9). Figure 1 shows that a substantial proportion of the population had HPA axis activation that far exceeded the biochemical definition in use. Figure 2 demonstrates the proportion of study participants who could be classified as having significant HPA axis activation according to other, potentially more stringent, definitions described in the literature. These alternate salivary cortisol-based definitions of HPA axis activation are drawn from dynamic tests of maximal adrenal reserve. 12, 14, 15 Even using cut-offs that take obesity-related hypercortisolism and maximal physiologic adrenal stimulation into account (definitions 2 and 3), it may be seen that almost 20% of subjects could still be considered as having significant HPA axis activation one month following hospital discharge for ACS. Figure 3 shows detailed data on LNSC measures in patients with and without elevated levels of depression as determined by the baseline questionnaire. It is noteworthy that the mean LNSC did not differ according to depression status and that many participants without major depressive symptoms still had marked HPA axis activation. There was a trend towards higher HADS Depression scores in patients with prolonged HPA axis activation but it did not reach statistical significance (p ¼ 0.06).
Discussion
This is the first study to examine HPA axis activation in a large sample of patients with ACS after discharge Definition of HPA axis activation from hospital. We found that 32% of patients had significant HPA axis activation by the primary definition (LNSC levels within the range of what may be seen in Cushing's syndrome). Seventeen percent of participants had LNSC levels that were more than 200-300% above this cut-off. Using more conservative definitions of HPA axis activation, a substantial proportion of patients still had profoundly abnormally high mean LNSC measurements. Whether this elevation in LNSC reflects a persistent activation or a re-activation of the HPA axis is not known, but the association of LNSC with traditional risk factors and previous CVD suggest that increased HPA activity may be a biomarker or a potential mechanism in premature ACS. Our demonstration of an association of elevated LNSC with prior CVD is not surprising as hypercortisolism has been associated with a number of ''traditional'' CVD risk factors. 16, 17 In addition, cortisol may also be an independent risk factor for CVD. Reynolds et al. performed a cohort study of 919 patients with type 2 diabetes and found that, after adjusting for CVD risk factors, elevated plasma cortisol levels (greater than 1.05 nmol/l) were associated with a history of ischemic heart disease (odds ratio (OR) 1.58, p ¼ 0.03). 18 Besides systemic effects on sympathetic tone and metabolism, cortisol also has numerous local effects on blood vessel development, tone, and remodelling. 19 Furthermore, some postulate that elevated cortisol is associated with a ''sub-clinical'' inflammatory state that contributes to atherosclerosis through immune cytokines. 20 We found that patients who smoke were more likely to have HPA axis activation. Smoking has been shown to be associated with higher LNSC levels. 21, 22 We also found that patients with abnormally high LNSC levels had significantly higher HbA1C levels and lower HDL values; although the overall incidence of diabetes and dyslipidemia did not significantly differ between the groups. Oltmanns et al. found a positive association between salivary cortisol and HbA1C levels in 190 type 2 diabetics. 23 The negative association between cortisol levels and HDL values has been replicated in other studies, 24, 25 and is likely related to increased oxidation of free fatty acids. 17 We found that a higher proportion of patients with a hyper-active HPA axis had co-morbid peripheral vascular disease. Interestingly, the only other study examining random serum cortisol levels and peripheral vascular disease found no link between the variables in 278 patients. 26 It is possible that diurnal variation in cortisol levels affected the results in that study since a large study of 1866 individuals did find an association between carotid atherosclerosis and LNSC. 27 Abnormally high cortisol levels have been investigated as both a potential risk factor for CVD as well as a marker of prognosis. Previous work has shown that the magnitude of serum cortisol elevation is directly related to the severity of the infarction in the acute phase. 28 In our study, we found no association between the severity of ACS, as defined by the TIMI and GRACE scores, and elevated post-discharge LNSC levels. It is possible that prolonged HPA axis activity is a reflection of the propensity to develop coronary artery disease rather than in response to the acute effects of the ACS event. A case-control study by Pereg et al. measured cortisol contents in hair samples of patients who presented with acute myocardial infarctions. 29 As previous studies have demonstrated that cortisol remains stable in hair follicles, 30 the study used hair as a retrospective record of cortisol production over the last three months. After adjusting for other CVD risk factors, elevated hair cortisol concentrations were higher in patients with acute myocardial infarctions compared to patients admitted for other reasons. 29 The results of this study could suggest a future role for monitoring HPA axis activation to predict CVD risk.
The link between the HPA axis and mental health is well established. 3, 4, 31 However, our analysis found that neither elevated depressive nor anxious symptoms (together or separately) could explain the strikingly high proportion of patients with abnormal HPA axis activity. Although there was a trend towards higher HADS Depression Scores in patients with prolonged HPA axis activation, this did not reach the level of statistical significance (p ¼ 0.07). These inconsistent results could be due to the fact that we identified patients based on self-report questionnaires which may have led to a misclassification of the proportion of patients with a possible mental health issue. Furthermore, the sample size may have been underpowered to detect a difference in HADS scores. Our cohort had a high apparent incidence of psychological morbidity as 142 (43.4%) individuals had significantly elevated levels of depression or anxiety symptoms while the estimated combined prevalence of clinical anxiety and mood disorders is only 9.4% in Canada. 32 Furthermore, the link between CVD and mental illness is complex and cannot necessarily be ascribed to a single variable or process. 31 The elevated cortisol levels in patients with premature ACS could be due to a ''pro-inflammatory'' state from a variety of factors besides psychological comorbidities.
It is appealing to consider LNSC or HPA activity as potential marker of CVD or CVD risk although it must be stated that the acute and chronic adaptations of the HPA axis to critical illness are complex. 33, 34 Previous studies have demonstrated elevated serum cortisol levels in hospitalized ACS patients. Bain et al. measured random serum cortisol levels in 70 patients admitted to a coronary care unit with myocardial infarction. 28 They found that total serum cortisol levels normalize within 72 hours after ACS presentation. 28 A more recent study by Nito et al. followed random serum cortisol levels in 36 patients with ACS on days 1, 3, 5, 7 after admission. 35 In that study, 26 patients (72.2%) had normal total serum cortisol levels after three days. 35 Seven days after admission, only two (5.5%) patients had abnormally high total serum cortisol levels. 35 Our study is unique in comparison to previous work as we examined salivary cortisol levels-rather than serum levels-several weeks after the acute event. The increased statistical power and the differences in measurement technique and population may explain the apparent discrepancy in results between our study and other studies. The use of LNSC in this cohort of ACS patients was deliberate as ''bioavailable'' cortisol levels do not always correspond with total cortisol levels. In patients undergoing significant physiologic stress, which could parallel an ACS, cortisol binding globulin levels drop, 36 resulting in artificially low total cortisol levels. 37 Of note, these prior studies were limited by smaller sample sizes and thus may have had insufficient power to detect a real abnormality. One other possibility might be that HPA axis activity briefly normalizes following treatment of an acute event, only to later rise again to high levels as a consequence of prolonged psychophysiological responses to illness once the patient is back in their home environment.
Our study represents the largest group of patients in which HPA axis activity has been measured post-ACS. The GENESIS-PRAXY database has many biological and psychosocial measurements that have allowed for an assessment of a variety of traditional and non-traditional CVD risk factors. The patients received comprehensive follow-up and were monitored for a full year after their ACS event. However, there are a number of important study limitations. There was some degree of variability in the timing of LNSC samples collection. Furthermore, each patient had only two LNSC measurements. Both of these factors could affect the accuracy of our HPA activation diagnoses and classification and may not sufficiently accurately reflect the full spectrum of HPA activity over the 90 days post hospital discharge period. Future studies should follow cortisol levels longitudinally to determine if patients return to ''normal'' levels. True endogenous hypercortisolism (Cushing's disease) is exceedingly rare and therefore unlikely to confound the study measurements. In this study we only examined the relationship between HPA axis activity and depression and anxiety scores. Future investigations should explore associations between cortisol and the presence of actual mood and/or anxiety disorders (measured using validated interviews) and other psychosocial comorbidities (such as post-traumatic-stress-disorder) to directly explore the relationship between psychiatric disease, HPA axis activity and CVD outcomes.
Conclusion
This study demonstrates that almost one-third of patients presenting with premature ACS have abnormal LNSC levels following hospital discharge. Furthermore, the marked elevation in LNSC was not associated with comorbid depression or anxiety. We found that abnormally activated HPA axis may be associated with some of traditional CVD risk factors. Further investigation is required to confirm if HPA axis activity, as reflected by serial salivary cortisol measurements, is a novel risk factor for CVD or whether it plays a pathogenic role in the known link between psychosocial stressors and poor CVD outcomes.
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